Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.81 |
| ▸ | P2RX1 | P51575 | 9/20 | 0.69 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.69 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.69 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14363353 | 0.90 | KCNMA1 (0.66) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL31093979 | 0.87 | KCNMA1 (0.71) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL16147455 | 0.87 | KCNMA1 (0.71) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL10589125 | 0.87 | KCNMA1 (0.81) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL15026045 | 0.87 | KCNMA1 (0.76) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL30771727 | 0.87 | KCNMA1 (0.76) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL24460172 | 0.86 | P2RX1 (0.70) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL30771752 | 0.86 | P2RX1 (0.70) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL330023 | 0.86 | TMPRSS4 (0.83) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL8042390 | 0.85 | KMT2A (0.81) | KCNMA1P2RX1P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | claimed |
| EP-3313388-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | Duke University (US) | 2018-05-02 | — | — | EP | claimed |
| WO-2016210289-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | KCNMA1 1478/4885P2RX1 910/4885TMPRSS4 2067/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3082/4885P2RX1 1459/4885TMPRSS4 1813/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885TMPRSS4 1647/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885TMPRSS4 1647/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNMA1 1490/4885P2RX1 901/4885TMPRSS4 2073/4885 |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | KCNMA1 4847/4885P2RX1 3423/4885TMPRSS4 2074/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | KCNMA1 3380/4885P2RX1 1538/4885TMPRSS4 1647/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | KCNMA1 1417/4885P2RX1 848/4885TMPRSS4 2146/4885 |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | SFRP1, FZD7, WNT1 | KCNMA1 4847/4885P2RX1 3423/4885TMPRSS4 2074/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNMA1 1478/4885P2RX1 910/4885TMPRSS4 2067/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | KCNMA1 2705/4885P2RX1 2316/4885TMPRSS4 3292/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | KCNMA1 1478/4885P2RX1 910/4885TMPRSS4 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.